Riskpilot← Back to searchSign inGet full accessAdvocoTox AB
ABActiveOrg 5567841597Mörby Centrum 7trEngineering activities and related technical consultancy · NACE 7112Est. 20092 employees
Revenue 2024
SEK 1,8M
-5% vs 2023
EBITDA margin
8.9%
+68% vs 2023
Equity ratio
59.7%
Financial strength
Net profit 2024
SEK 271K
+386% vs 2023
| Revenue | SEK 1,8M | -5% |
| EBITDA | SEK 165K | +68% |
| Net profit | SEK 271K | +386% |
| Total assets | SEK 693K | +7% |
| Equity | SEK 414K | +70% |
| Employees | 2 | — |
Legal name
AdvocoTox AB
Org number
5567841597
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
17 juni 2009
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Clemedson, Ulrika Cecilia
Company purpose
Bolaget ska bedriva konsultverksamhet rörande kemikalier och kemiska produkters effekter på hälsa och miljö för att hjälpa företag, myndigheter och andra organisationer. Bolagets verksamhet innefattar även förvaltning av fast och lös egendom.
Address
Mörby Centrum 7tr
Phone
+46706019189
Email
cecilia.clemedson@advocotox.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 180 | 2 069 | 1 963 | 1 930 | 1 840 |
| Staff expenses | — | — | −1 708 | −1 556 | −1 499 |
| EBITDA | 490 | 74 | −47 | 98 | 165 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 490 | 74 | −47 | 98 | 165 |
| Net financials | −2 | −1 | −1 | 0 | 1 |
| Profit before tax | 573 | 73 | −8 | 72 | 346 |
| Tax | −126 | −16 | — | −17 | −75 |
| Net profit | 447 | 57 | −8 | 56 | 271 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 223 | 901 | 572 | 650 | 693 |
| Equity | 688 | 345 | 187 | 243 | 414 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 340 | 361 | 231 | 227 | 279 |
| Total debt | 340 | 361 | 231 | 227 | 279 |
EBITDA margin
8.9%
This company
15.8%
Market median
-44% vs market
20202024
Equity ratio
59.7%
This company
38.2%
Market median
+56% vs market
20202024
Return on equity
65.4%
This company
18.4%
Market median
+255% vs market
20202024
Net profit margin
14.7%
This company
8.1%
Market median
+81% vs market
20202024
Asset turnover
2.66×
This company
1.12×
Market median
+138% vs market
20202024
Debt / equity
0.67×
This company
0.62×
Market median
+8% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
UC Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2025 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AdvocoTox AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulrika Cecilia Clemedson | Chief Executive Officer | 0 companies |
| Björn Ingemarsson | Deputy Board Member | 0 companies |
| Sigrid Barbro Maria Ingemarsson | Deputy Board Member | 0 companies |